AU596864B2

AU596864B2 – The use of 2′,3′-dideoxycytidin-2′-ene(2′,3′-dideoxy-2′,3′- didehydrocytidine) in treating patients infected with retroviruses
– Google Patents

AU596864B2 – The use of 2′,3′-dideoxycytidin-2′-ene(2′,3′-dideoxy-2′,3′- didehydrocytidine) in treating patients infected with retroviruses
– Google Patents
The use of 2′,3′-dideoxycytidin-2′-ene(2′,3′-dideoxy-2′,3′- didehydrocytidine) in treating patients infected with retroviruses

Download PDF
Info

Publication number
AU596864B2

AU596864B2
AU77977/87A
AU7797787A
AU596864B2
AU 596864 B2
AU596864 B2
AU 596864B2
AU 77977/87 A
AU77977/87 A
AU 77977/87A
AU 7797787 A
AU7797787 A
AU 7797787A
AU 596864 B2
AU596864 B2
AU 596864B2
Authority
AU
Australia
Prior art keywords
ene
dideoxy
dideoxycytidin
didehydrocytidine
virus
Prior art date
1986-09-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU77977/87A
Other versions

AU7797787A
(en

Inventor
Tai-Shun Lin
William H. Prusoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yale University

Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1986-09-24
Filing date
1987-09-04
Publication date
1990-05-17

1987-09-04
Application filed by Yale University
filed
Critical
Yale University

1988-03-31
Publication of AU7797787A
publication
Critical
patent/AU7797787A/en

1990-05-17
Application granted
granted
Critical

1990-05-17
Publication of AU596864B2
publication
Critical
patent/AU596864B2/en

2007-09-04
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/70—Carbohydrates; Sugars; Derivatives thereof

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P31/12—Antivirals

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P31/12—Antivirals

A61P31/14—Antivirals for RNA viruses

A61P31/18—Antivirals for RNA viruses for HIV

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings

C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention relates to a pharmaceutical composition for treating warm blooded animals infected with a retrovirus, comprising an anti-retroviral effective amount of 2′, 3′-dideoxycytidin-2′-ene or a pharmaceutical acceptable salt thereof, either alone or in admixture with usual additives.

Description

4 c I COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952 Form SUBSTITUTE COMPLETE SPECIFICATION FOR OFFICE USE 59 864 Short Title: Int. Cl: Application Number: Lodged: Complete Specification-Lodged: Accepted: Lapsed: Published: Priority: Related Art: ii
I
F
r
I;:
~cr o 10 0a 0 O 0e 0 0 0 a Name of Applicant: Address of Applicant: Actual Inventor: Address for Service: TO BE COMPLETED BY APPLICANT YALE UNIVERSITY New Haven, Connecticut, U.S.A.
Tai-Shun Lin and William H. Prusoff GRIFFITH HASSEL FRAZER 71 YORK STREET SYDNEY NSW 2000
AUSTRALIA
Complete Specification for the invention entitled: THE USE OF 2′,3′-DIDEOXYCYTIDIN-2′-ENE(2,3′- DIDEOXY-2′,3′-DIDEHYDROCYTIDINE) IN TREATING PATIENTS INFECTED WITH
RETROVIRUSES
The following statement is a full description of this invention, including the best method of performing it known to me/us:- 5347A:rk
T
_I_
f GOVERNMENT RIGHTS This invention was made with United States Government support under Grant CA-28852 from the NIH. The United States Government has certain rights in this invention.
BACKGROUND OF THE INVENTION Field of the Invention The present invention concerns the use of nucleoside 2′,3′-dideoxycytidin-2′-ene (2′,3′-dideoxy-2′,3′-didehydrocytidine) in treating patients infected with retroviruses, especially AIDS.
Background Information The etiological agent of acquired immunodeficiency syndrome (“AIDS”) is a retrovirus called lymphadenopathy-associated virus (LAV) Barre-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W.
Rozenbaum and L. Montagnier, Science, 220, 868-870 (1983)) or human T lymphotropic virus III (HTLV III) Popovic, M.G. Sarngadharan, E. Read and R.C. Gallo, Science, 224, 0 ’20 497-508 (1984)). Presently, the best evidence supports the 0 o concept that these are either the same virus or closely related variants Ratner, W. Haseltine, R. Patarca et al, 0° Nature, 313, 227-285 (1985).
2′,3′-Dideoxycytidin-2′-ene was first synthesized by “a 25 Horowitz et al. Horwitz, J. Chua, M. Noel, J.T.
Donatti, J. Org. Chem., 32, 817 (1967)).
Hiroaki Mitsuya and Samuel Broder, Proc. Natl. Acad.
Sci. USA, 83, 1911-1915, March 1986, described the testing of purine and pyrimidine nucleoside derivatives, namely, o 0 30 2′,3′-dideoxynucleosides to attempt to inhibit the #0 infectivity and cytopathic effect of human T-lymphotropic virus type III (HTLV-III/LAV) in vitro.
00*000 SUMMARY OF THE INVENTION 10 The present invention is directed to the treatment of 35 warm blooded animals, including humans, infected with a 0 retrovirus, comprising administering to a warm blood animal, a human patient, an anti-retroviral effective amount of 2′,3′-dideoxycytidin-2′-ene 5550S/1S. -1Axi (2′,3′-dideoxy-2′,3′-didehydrocytidine) and pharmaceutically acceptable salts thereof, either alone or in admixture with a diluent or in the form of a medicament.
DETAILED DESCRIPTION OF THE INVENTION The structure of 2′,3′-dideoxycytidin-2′-ene (2′,3′-dideoxy-2′,3′-didehydrocytidine) is as follows:
NH
2
N
HO N
O
2′,3′-dideoxycytidin-2′-ene (2′,3′-dideoxy-2′,3′-didehydrocytidine) can be prepared according to the following reaction scheme: 8 I S ‘2 0 a 0, o o o o* 25 0 4 0 a p.35 o 03 0 0 C a 0
NH
0; NI
HO
1
N
1
II
\N
Ac 2 0 1 Py
A
s) 0
HN
OkN 2
NH
2 4 0 q AcO ~J 1 NH2OH-dioxane 2. NH 2 -MeOH 3 In the above scheme, the following steps are conducted: Compound 1 (2′,3′-dideoxyuridin-2′-ene> is acetylated with acetic anhydride (Ac20) in pyridine however, can be carried 5550S/ls.
-2out with actylchloride in a solvent having triethylamine present, to yield the corresponding acetate 5′-O-acetyl-2′,3′-dideoxyuridine-2′-ene which is then treated with 4-chlorophenyl phosphorodichloridate and 1,2,4-triazole in pyridine at room temperature to yield the 4-triazolylpyrimidinone derivative 3. Subsequent treatment of the 4-triazolylpyrimidinone derivative with aqueous ammonia in dioxane is conducted for several hours to several days and then methanolic ammonia is added overnight at room temperature to yield 2′,3′-dideoxycytidin-2′-ene (2′,3′-dideoxy-2’3′-didehydrocytidine) (compound 4).
Applicants have discovered that 2′,3′-dideoxycytidin-2′-ene (2′,3′-dideoxy-2′,3′-didehvdrocytidine) has antiviral activity against retroviruses, murine leukemia virus and HTLV III/LAV virus (the AIDS virus).
Retroviruses are RNA viruses whose genome contains copies of single-stranded RNA. The virion contains reverse transcriptase. Non-limiting examples of retroviruses include leukemia and sarcoma viruses of animals, foamy viruses of primates and some slow viruses, visna and maedi of sheep.
0 2′,3′-dideoxycytidin-2′-ene has a much better water o solubility than that of 3′-azido-3′-deoxythymidine (AZT).
In addition, 2′,3′-dideoxycytidin-2′-ene can be readily o converted to the corresponding hydrochloride and other salts, which will further enhance its water solubility.
Water solubility is a critical factor for drug formulation.
4 The active compound namely, 2′,3′-dideoxycytidin-2′-ene (2′,3′-dideoxy-2′,3′-didehydiocytidine) can be administered as a medicament.
SThe medicament can be in the form of tablets (including lozenges and granules), dragees, capsules, pills, ampoules or suppositories comprising the compound of the invention.
“Medicament” as used herein means physically discrete coherent portions suitable for medical administration.
“Medicament in dosage unit form” as used herein means 5550S/ls.
physically discrete coherent units suitable for medical administration, each containing a daily dose or a multiple (up to four times) or a sub-multiple (down to a fortieth) of a daily dose of the compound of the invention in association with a carrier and/or enclosed within an envelope. Whether the medicament contains a daily dose, or for example, a half, a third or a quarter of a daily dose will depend on whether the medicament is to be administered once or, for example, twice, three times or four times a day, respectively.
The active compound can also be administered as suspensions, solutions and emulsions of the active compound in aqueous or non-aqueous diluents, syrups, granules or powders.
Diluents that can be used in pharmaceutical compositions granulates) containing the active compound adapted to be formed into tablets, dragees, capsules and pills include the following: fillers and extenders, starch, sugars, mannitol and silicic acid; 20 binding agents, carboxymethyl cellulose and other cellulose derivatives, alginates, gelatine and polyvinyl 1 pyrrolidone; moisturizing agents, glycerol; (d) disintegrating agents, agaragar, calcium carbonate and sodium bicarbonate; agents for retarding dissolution, “25 paraffin; resorption accelerators, e.g., quaternary ammonium compounds; surface active agents, cetyl alcohol, glycerol monostearate; adsorptive carriers, kaolin and bentonite; lubricants, e.g., talc, calcium and magnesium stearate and solid polyethyl glycols.
The tablets, dragees, capsules and pills comprising the active compound can have the customary coatings, envelopes and protective matrices, which may contain opacifiers. They 0 can be so constituted that they release the active 35 ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time. The coatings, envelopes and protective matrices may be made, for example, from polymeric substances or waxes.
ata t at a, a” aY 0.4 0
C
Qa 0′ 000.4.
0 5550S/ls.
I: The active ingredient can also be made up in microencapsulated form together, with one or several of the above-mentioned diluents.
The diluents to be used in pharmaceutical compositions adapted to be formed into suppositories can, for example, be the usual water-soluble diluents, such as polyethylene glycols and fats cocoa oil and high esters, e.g.,
C
1 4-alcohol with C16-fatty acid) or mixtures of these diluents.
The pharmaceutical compositions which are solutions and emulsions can, for example, contain the customary diluents (with, of course, the above-mentioned exclusion of solvents having a molecular weight below 200, except in the presence of a surface-active agent), such as solvents, dissolving agents and emulsifiers. Specific non-limiting examples of such diluents are water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (for example, ground nut oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitol or mixtures thereof.
For parenteral administration, solutions and emulsions g” should be sterile and, if appropriate, blood-isotonic.
The pharmaceutical compositions which are suspensions o 25 can contain the usual diluents, such as liquid diluents, o water, ethyl alcohol, propylene glycol, surface-active agents ethoxylated isosteraryl alcohols, polyoxyethylene sorbite and sorbitane ester, I microcrystalline cellulose, aluminium metahydroxide, o*o “0 bentonite, agar-agar and tragacanth or mixtures thereof.
o The pharmaceutical compositions can also contain coloring agents and preservatives, as well as perfumes and flavoring additions peppermint oil and eucalyptus oil) and sweetening agents saccharin and aspartame).
35 The pharmaceutical compositions generally contain from 0.5 to 90% of the active ingredient by weight of the total 0 0 composition.
5550S/ls.
11 1~P In addition to the active compound, the pharmaceutical compositions and medicaments can also contain other pharmaceutically active compounds.
Any diluent in the medicaments of the present invention may be any of those mentioned above in relation to the pharmaceutical compositions. Such medicaments may include solvents of molecular weight less than 200 as the sole diluent.
The preferred daily dose for administration of the medicaments of the invention is 2.5 to 250 mg of active ingredient in the case of intravenous administration and to 250 mg of active ingredient in the case of oral administration.
It is envisaged that this active compound will be administered perorally, parenterally (for example, intramuscularly, intraperitoneally, subcutaneously or intravenously), rectally or locally, preferably orally or parenterally, especially perlingually or intravenously.
Preferred pharmaceutical compositions and medicaments are, therefore, those adapted for administration such as oral or parenteral administration. Administration in the method of the invention is preferably oral or parenteral administration.
In general, it has proved advantageous to administer i 25 intravenously amounts of from 0.01 mg to 10 mg/kg, preferably 0.05 to 5 mg/kg, of body weight per day and to administer orally 0.05 to 20 mg/kg, preferably 0.5 mg to mg/kg of body weight per day, to achieve effective results.
Nevertheless, it can at times be necessary to deviate from those dosage rates, and in particular to do so as a function of the nature and body weight of the human or animal subject to be treated, the individual reaction of this subject to the treatment, type of formulation in which the active ingredient is administered, the mode in which the o o35 administration is carried out and the point in the progress of the disease or interval at which it is to be 0 administered. Thus, it may in some case suffice to use less than the above-mentioned minimum dosage rate, whilst other 5550S/ls.
q I C- I cases the upper limit mentioned must be exceeded to achieve the desired results. Where larger amounts are administered, it may be advisable to divide these into several individual administrations over the course of the day.
The invention will now be described with reference to the following non-limiting examples.
Example 1 Synthesis of 2′,3′-Dideoxycytidin-2′-ene Acetic anhydride (1.00g, 10.0 mmol) was added slowly to a stirred solution of compound 1 (0.42 g, 2.00 mmol) in mL of pyridine at 0°C (ice-bath). The resultant solution was allowed to stand overnight at 4 0 C. The solvent and the excess acetic anhydride were removed in vacuo. The remaining residue was dissolved in 50 mL of CHC1 3 washed in a separatory funnel with 50 mL-portions of H 2 0 (3 times), saturated NaHCO 3 (2 times), and H 2 0 again (2 times). The CHC13 solution was clarified with Norit, dried with anhydrous MgSO 4 and filtered. The filtrate was then concentrated to a residue which was used immediately without further purification for the next preparation.
The acetate was dissolved in 10 mL of pyridine. While stirring in a cold-water bath, 4-chlorophenyl o phosphorodichloridate (0.74 g 3.00 mmol) was added dropwise, followed by the addition of 1,2,4-triazole (0.41 g, 6.00 o 25 mmol). The mixture was stirred at room temperature for 3 days and then concentrated under reduced pressure (approximately 30 0 The resulting residue was dissolved in 25 mL of CH2C1 2 washed with 25 mL of H 2 0 (2 times) Ooo and 50% NaHCO 3 solution (25 mL). The CH 2 C1 2 solution was clarified with Norit, dried (MgSO 4 and filtered. The a filtrate was evaporated to dryness in vacuo to yield a glassy residue (4-triazolylpyrimidinone derivative), which was dissolved in 25 mL of NH OH-dioxane The 0 4 o mixture was stirred for 5 hours at room temperature in a S095 Wheaton pressure bottle. This solution was then concentrated and the remaining residue was stirred overnight in the pressure bottle at room temperature in 25 m of in the pressure bottle at room temperature in 25 mL of 5550S/ls.
-7i saturated methanolic ammonia. The solution was then reduced to a small volume in vacuo and chromatographed on a silica gel column (CHCl 3 -MeOH, 3:1, Rf0.34) to yield 0.17 g based on compound 1) of product: mp 163-165oC; UV (0.1NHC1) Xmax 275 nm 11,340), min 237 nm; UV (0.1N NaOH) Amax 267 nm e7,010) Xmin 247 nm; NMR (Me 2 SO-d 6 63,56 2H, 4.75 1H, 4.95 (br, s, 1H, 5′-OH, D 2 0 exchangeable), 5.68 1H, 5.88 1H, vinyl), 6.33 1H, vinyl), 6.89 1H, 7.12-7.19 (br, d, 1H, 4-NH 2
D
2 0 exchangeable), 7.68 1H, 6-H).
The starting compound 1 was prepared from 2′-deoxyuridine by the methodology of Horwitz et al. (J.P.
Horwitz, J. Chua, M. Noel, J.T. Donnatti, J. Orq. Chem., 32, 817, (1967)).
Example 2: Biological Activity Assay Procedure For Antiviral Screening Against Moloney Murine Leukemia Virus (M-MuLV) by XC- Assay: The XC assay system is an indirect method for quantitation of murine-leukemia virus (MuLV) originally described by V. Klement et al, Proc. Nat’1. Acad Sci., 63, 753-758, (1969) and modified by W. Rowe et al, Virology, 42, 1136-1139, (1970). This test is based on the development of I °o syncytial changes in the XC cell line when it is co-cultivated with mouse fibroblast cells (SC-1 cells) productively infected with MuLV. The XC cell line was derived from a rat tumor induced by the Prague strain of Rous Sarcomo Virus (RSV) Svobada et al, Folia Biol., 9, 77-81, (1983)). This cell line contains the RSV genome, but 1,o 30 does not produce infectious virus in the absence of a helper virus. 10E6 SC–1 cells were seeded in Earls’ Mininum Essential Medium (EMEM)-10% Fetal Bovine Serum (FBS) onto mm petri dishes. The following day, the cells were inoculated with 0.5 mL of a virus dilution containing 25 yjg/mL of DEAE-dextran. The dishes were maintained for one hour at 37 0 C in a humidified 5% CO 2 incubator. The virus inoculum was then removed and replaced with 5 m virus inoculum was then removed and replaced with 5 mL 5550S/ls.
i i rmsllrmr=S;m of medium containing appropriate concentration of the test compound (two dishes/concentration). A medium containing FBS was added to the virus control dishes. The medium (with or without the test compound) was changed at 48 hours.
Five days after virus inoculation, the culture fluid was decanted and the cells were irradiated with a “GE” 2 germicidal bulb for 30 seconds (60 ergs/mm /sec UV-light). The cultures were immediately overlaid with 106 XC cells in 5 mL of EMEM-10% FBS/dish. The medium was changed at 2 day intervals. Four days after XC cells addition, cultures were simultaneously fixed and stained with Giemsa stain for 10-15 minutes.
Virus plaques areas of the cell sheet containing syncytial cells or focal masses of multinucleated giant cells) were counted using an inverted microscope. The percent inhibition in virus plaque number at each drug concentration was calculated as follows: Inhibition= 100 average of syncytia at cone. of test compound X 100 14 average of syncytia in the virus control 00 0 0t 0o (a 0a 0 0
(ID
50 Accumulative Inhibition using Reed-Muench Method ED50: Effective Dose to inhibit The median inhibitory dose (ID 50 of each compound was calculated from the percent inhibition results using the Reed-Muench Method.
The antiviral activity of 2′,3′-dideoxycytidin-2′-ene compared against 2′,3′-dideoxycytidine is shown as follows in Table 1. 2′,3′-Dideoxycytidine is a known potent compound against HTLV-III/LAV virus in culture (Mitsuya and Broder, surpra).
00 00 Stt0 35 0 0 Q f Q 5550S/ls.
-9- Ir- r a~i~irrs Table 1
ID
50 1 m) (Moloney Murine Leukemia Virus) Compound 2′,3′-dideoxycytidin-2′-ene 2′,3′-didexocytidine 3.7 Example 3: Antiviral Activity of 2′,3′-dideoxy-2′,3’didehydrocytidine (2′,3′-didexocytidin-2′-ene) A. Cellular Assay of Inhibition of HTLV-III/LAV (cytopathic effect), Fluorescence, Viability) Nucleoside Analogs: One millimolar solutions were t 7 4 0, I 77 o 7 i4 nr F~-i- Cs~d 777 0 a 03 prepared in glass distilled water and filter sterilized through 0.
2 p filters. Subsequent dilutions were prepared in RPMI 1640 medium containing 15% fetal calf serum, penicillin, streptomycin and glutamine.
Cell Cultures: The HTLV-1 transformed cell line MT-2 (MT-2 cells are lymphocytes dervied from placenta cord blood which were transformed by HTLV-I) were suspended at 6 0.5×10 cells/ml in each of the media samples having the drug concentrations outlined in Table 2. Cultures were incubated in the drug overnight (approximately 9 hours) in 24 well TC plates at 0.66 ml/well.
Virus: HTLV-III/LAV prepared in PHA (phytohemagglutinin A) blasts, titering approximately 105 infectious units/ml was added in 10 pl amounts to 0.66 ml cultures. PHA stimulates lymphocytes to proliferate and undergo blast transformation. One thousand infectious center forming units were added to duplicate wells of each drug concentration. A cell control was mock-infected at each drug concentration.
5550S/ls.
i r r Assay: On day 7 post-infection, day 8 post-drug treatment, the cultures were visually inspected for cytopathic effect and harvested individually by centrifugation at 1200 RPM in a TJ6 centrifuge, using aerosolve cannisters. The cells were resuspended in 200 pl PBS. 20 1l from each duplicate were pooled and stained for viability using the trypan blue exclusion method. 20 pl of each duplicate were spotted onto multiwell slides, dried and acetone-fixed for fluorescent studies.
Fluorescent Assay: Acetone-fixed cells were stained by monoclonal antibody apl8 (monoclonal antibody apl 8 is directed against HTLV III virus), which had been directly conjegated and contained Evans blue counterstain added to the monoclonal diluent. Cell counts reflect one field from each duplicate for each drug concentration.
It o o 0 Io 6 20 0 I 0 40 ¢J 25 4 09 0 a a o 0 o 0*9 0 25 04 0 Q4 Conclusion: The data in Table 2 show that 2′,3′-dideoxy-2′,3′-didehydrocytidine (2′,3′-dideoxycytidin-2′-ene) has antiviral activity against the HTLV-III/LAV infection in vitro and that the effective dose falls in the same range as 2′,3′-dideoxycytidine.
Table 2 Compound Fluoresence Apparent CPE Viable Cells p1M 1.0 uM 0.5 1M 1.0 IM. 0.5 M 1.01 aoo 04U4 0 30 S. 0 <0 0 30 04 a ooaa d00000 o 2',2'-dideoxycytidine 2',3'-dideoxy- 2',3'-didehydrocytidine 3'-dideoxycytidin-2'-ene) 4.3 0.3 0.2 0.1 40 10 1.0 0.0 75 -96 5.6 5.5 1.1 90 0.5 22 \\o 01%' 5550S>